title: Safety and efficacy of sibutramine in overweight Hispanic patients with hypertension.
abstract: This 6-month randomized study evaluated the safety and efficacy of sibutramine in 57 overweight Hispanic patients with hypertension. Following a 2-week washout to confirm the diagnosis of hypertension, antihypertensive medication was adjusted to achieve a blood pressure less than 140/90 mm Hg before institution of either sibutramine 10 mg or placebo once a day. A body mass index in excess of 27 kg/m2 was required for entry. At study end, weight had changed from 75.4+/-9.6 to 70.0+/-9.5 kg in the sibutramine group and from 77.9+/-9.0 to 74.5+/-9.4 kg in the placebo group. In the sibutramine group, systolic blood pressure was 127.8+/-5.8 mm Hg after stabilization and 125.2+/-8.5 mm Hg after completion of the trial; respective values for diastolic blood pressure were 82.4+/-3.7 and 81.5+/-4.6 mm Hg. With placebo, blood pressure dropped from 129.0+/-7.1/80.9+/-4.9 mm Hg to 122.8+/-9.7/80.3+/-5.4 mm Hg at the same timepoints. In the sibutramine group, 14 patients reported 21 adverse events, most frequently headache (n=5), constipation (n=4), and dry mouth (n=4). In the placebo group, 13 patients had 20 adverse events. Sibutramine is safe and effective in overweight Hispanic patients with hypertension, but monitoring of blood pressure and titration of antihypertensive medication are necessary.
authors.affiliation: Endocrinology Service, General Hospital of Mexico, Mexico City, Mexico.
authors.forename: Guillermo
authors.initials: G
authors.lastname: Fanghänel
authors.forename: Leonides
authors.initials: L
authors.lastname: Cortinas
authors.forename: Leticia
authors.initials: L
authors.lastname: Sánchez-Reyes
authors.forename: Rosario
authors.initials: R
authors.lastname: Gómez-Santos
authors.forename: Enrique
authors.initials: E
authors.lastname: Campos-Franco
authors.forename: Arturo
authors.initials: A
authors.lastname: Berber
mesh_terms: D000328:Adult; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001067:Appetite Depressants / Q000009:adverse effects / Q000627:therapeutic use*; D001794:Blood Pressure / Q000502:physiology; D015992:Body Mass Index; D001835:Body Weight; D003503:Cyclobutanes / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000503:physiopathology / Q000517:prevention & control*; D008297:Male; D008800:Mexico; D008875:Middle Aged; D009765:Obesity / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D010919:Placebos; D016896:Treatment Outcome; D015431:Weight Loss / Q000187:drug effects
chemical_list: D000959:Antihypertensive Agents; D001067:Appetite Depressants; D003503:Cyclobutanes; D010919:Placebos; C058254:sibutramine